

References

**** Almus FE, Rao LV, Rapaport SI:***

Decreased inducibility of tissue factor activity on human umbilical vein endothelial cells cultured with Endothelial cell growth factor & heparin.

Thromb. Res. 50:339-344, 1988

**** Avidans Ms; Hunt BJ:***

point of care assessment of hemostasis after CPB: Lancet Sep. 25; 254 (9184): P 1124-5, 1999.

**** Avvisati G, Ten cate JW, Mandelli F.:***

Acute promyelocytic leukaemia. Br. J. Haematol; 81:315-20, 1992.

**** Baier RE:***

The organization of blood components near interfaces.

Ann NY Acad Sci:283:17-36, 1989.

**** Bajaj MS, Kuppuswamy MN, Saito H, et al.):***

Cultured normal human hepatocytes don't synthesize lipoprotein-associated coagulation inhibitor: Evidence that endothelium is the principal site of its synthesis. Dro Natl Acad.

Sci 87:8869-8873, 1990.

**** Bartels PC, schoor LM, Lomborts AJ:***

Screening for EDTA-dependent deviations in platelet counts and abnormality in platelet distribution histograms in pseudothrombocytopenia. Scand J clin labl Invest:57,629-36, 1997.

**** Bartlett RH, Kittredge D, Noyes BS JR, Willard RH III, Drinker PA, Harken De.:***

Development of a membrane oxygenator overcoming blood diffusion limitation.

J Thorac Cardiovasc Sure 58:795-800, 1990.

References

*** Barynin Iu A, Starkov IA, Khanin MA:**

Hemostasis; A mathematical model of spatial propagation of Blood coagulation
IZV Akad Nauk Ser Biol Jan-Feb; (1): P59-66, 1999.

*** Baufreton C, Jansen PG, Le Besnerais P, et al.:**

Heparin coated with aprotinin reduces Blood activation during CABG. Ann
thorac surg. 63:50-56, 1997.

*** Bell WR, Braine HG, Ness P, Kickler TS.:**

Improved survival in thrombocytopenic purpura-haemolytic uraemic
syndrome: clinical experience in 108 cases N Engl Med.; 325:398-403, 1991.

*** Benedetti M, De Caterina R, Bionda A. et al.:**

Blood-artificial surface interactions during cardiopulmonary bypass. A
comparative study of four oxygenators.
Int J Artif Organs; 13:488-497, 1990.

*** Bergqvist D:**

LMW heparins. J intern Med 240:63-72, 1996.

*** Bernstein EF, Marzec U, Johnston GG:**

Structural correlates of platelet functional damage by physical forces.
Trans Am Soc Artif Intern Organs; XXIII: 617-625, 1987.

*** Bick RL; Murano G:**

Physiology of hemostasis. Clin lab. Medical Dec; 14(4):P677-707 (1994).

*** Bittl JA, Storny J, Brinker JA, et al.:**

Hirudin as compared with heparin during coronary angioplasty for unstable
angina. Hirulog angioplasty study investigators. N Eng. J Med. 333:764- 769,
1995.

*** Blomback B:**

Fibrinogen and fibrin-proteins with complex roles in hemostasis and
thrombosis. Thromb Res Jule I; 83 (1): P 1-75 1996.

References

*** Blumberg N, Heal JM, Murphy P et al.:**

Association between transfusion of whole blood and recurrence of cancer. Br Med J 293:503, 1986.

*** Boisclair MD, Lane DA, Wilde JT, et al:**

a comparative evaluation of assays for markers of activated coagulation and or fibrinolysis: thrombin antithrombin complex, D-dimer and fibrinogen/fibrin fragments E antigen. Br J Haematol 74:47-479, 1990.

*** Boldt J:**

Acute platelet – Rich plasmapheresis for cardiac surgery. Journal of cardiothoracic and vascular anesthesia 9 (1), 79-88 1995.

*** Boyd PR, Sheedy KC, Henry JB:**

Type and screen: Use and effectiveness in elective surgery. Am J Clin Pathol 74:694, 1980.

*** Brister SJ, Buchanan MR:**

Heparinless CPB revisited: Answer strategy to avoid heparin related bleeding using dermatan sulphate.

J thorac Cardiovasc. Anesth 9:317-321, 1995.

*** Brister SJ, ofosu FA, Heigenhauser GJF, et al.:**

Is heparin the ideal anticoagulant for CPB? Dermatan sulphate may be alternative choice thromb haemost 71:468-473, 1994.

*** British committee for standards in Haematology:**

Guidelines on clinical use of leucodepleted blood components. Transfusion Med.; 8:59-71, 1998.

*** British committee for standards in hematology:**

Blood transfusion blood components.

Transfusion Med.; 8:59-71, 1998.

*** British committee for standards in hematology:**

Haemostasis and transfusion task force. The use and monitoring of heparin.

J cliu Pathol; 46:97-103, 1993.

References

- * Brown CH III, Lemuth RF, Hellums JD, Leverett LB, Alfrey CP:**
Response of human platelets to shear stress. Trans Am Soc Artif Intern Organs; XXI:35-38, 1975.
- * Butler BD:**
Biophysical aspects of gas bubbles in blood. Med Instrum: 19:59-62, 1985.
- * Butterworth JF, James RL, Kennedy DJ, et al.:**
Pharmacokinetics of α -aminocaproic acid in adult patients undergoing CABG. Anesthesiology 85:A 151, 1996.
- * Carr ME, Carr SL:**
At high heparin concentrations, protamine concentrations which reverse heparin anticoagulant effects are insufficient to reverse antiplatelet effects: Thromb Res 75:617-630, 1994.
- * Carr ME, Zekert SL:**
Abnormal clot retraction, altered fibrin structure and normal platelet function in multiple Myeloma. Am J physiol 266:H 1195-H 1201, 1994.
- * Carr ME, Zekert SL:**
Measurement of platelet mediated force development during plasma clot formation. Am J Med Sci 302:13-18, 1991.
- * Chomiak PN, Walenga JM, Koza MJ, et al.:**
Investigations for a thrombin inhibitor peptides an alternative to heparin in CPB. Circulation 88-II407-412, 1993.
- * Colantuoni G, Hellums JD, Moake JL, Alfrey CP Jr:**
The response of human platelets to shear stress at short exposure times. Trans Am Soc Artif Intern Organs; XXIII: 626:630, 1977.
- * Coleman RW, Hirsh J, Marder V.J. & et al.:**
Haemostasis and thrombosis, Basic principles and clinical practice. J.P Lippincott company, Philadelphia, 1987.

References

** Coller BS, Schnider man P:*

Clinical evaluation of hemorrhagic disorders: bleeding history and differential diagnosis of purpura.

In Haematology: Basic Principles and practice. Edited by Hoffman R, Benz EJJ, Shattil SJ, et al.: New York: Churchill livingstone:1252-1266, 1991.

** Coleman RW, Marder VJ, Hirsh J, et al:*

Overview of hemostasis: Hemostasis and thrombosis, 3rd edition. Philadelphia, JB Lippicott, pp3-18, 1994.

** Cook JJ, Niewiarowski S, Yanz, et al.:*

PE efficiently reverses heparin in rat without adverse effects of heparin-protomine complexes. Circulation 85:1102, 1992.

** Corash L:*

Measurement of platelet activation by fluorescence activation flow cytometry. Blood cells 160:97-108, 1990.

** Costello M, Stanczewski B, Vriesman P, Lucas T, Srinivasan S, Sawyer PN:*

Correlations between electrochemical and antithrombogenic characteristics of polyelectrolyte materials.

Trans Am Soc Artif Intern Organs; 16:1-6, 1990.

** Counts RB, Haisch C, Simon TL et al.:*

Hemostasis in massively transfused trauma patients. Ann Surg 190:91, 1991.

** Cull DL, Lally KP, Murphy KD:*

Compatibility of packed erythrocytes and ring's lactate solution. Surg Gynecol Obstet 173:12, 1991.

** D'Ambra MN, Risk SC:*

Aprotinin, erythropietin, and blood substitutes. Int Anesthesiol clin 28:237, 1990.

References

*** Dalamangas LC, slaughter TF:**

Ethylenediamine acetic acid dependent thrombocytopenia in a cardiac surgical patients. *Anesth. Analg.*, 86:1210-1, 1998.

*** Davies GC, Sobel M, Salzman EW:**

Elevated plasma fibrinopeptide A and thromboxane B2 levels during CPB. *Circulation* 61:808, 1980.

*** Defouw NJ, van Hinsbergh VW, de Jong YF, et al.):**

The interaction of activated protein C and thrombin with plasminogen activator inhibitor released from human endothelial cells, *Thromb Haemost* 57:176-182, 1987.

*** Delucia A 3rd, Wakefield TW, Andrews PC, et al.:**

Efficacy and toxicity of differentially charged polycationic protamine-like peptide for heparin anticoagulation reversal *J vasc. Surg* 18:49-60, 1993.

*** Despotis GJ, Goodnough LT:**

Management approaches to platelet-related microvascular bleeding in cardiac surgery. *Ann thorac surg*; 70(2 sup PL): Ps 20-32, Aug2000.

*** Di Cera E; Dang QD; Ayala YM:**

Molecular mechanism of thrombin function. *Cell Mol Life Sci Sep*; 53(9): P 701-30 (1997).

*** Dietrich W, Diltz G, Spannagel M, et al.:**

Influence of high dose aprotinin on anticoagulation. *Anesthesiology* 33:679, 1995.

*** Drinker PA, Bartlett RH, Bialer RM, Noyes BS Jr.:**

Augmentation of membrane gas transfer by induced secondary flow. *Surgery*: 66: 775-781, 1989.

*** Duckert F.: fibrin stabilizing factor (XIII):**

Consequence of its deficiency. *Thromb Haemost* B:115, 1989.

References

*** Edmunds LH, salzman EW:**

Hemostatic problems, transfusion therapy and CPB in surgical patients. In colman RW, Hirsh J, Marder VJ, Salzman EW (eds): Hemostasis and thrombosis: Basic principle and clinical practice, 3rd, ed, P956. Philadilphia, J B lippincott, 1994.

*** Eisele B, Lamy M.:**

Clinical experience with antithrombin III concentrates in critically ill patients with sepsis and organ failure. Semin Haemost Thromb; 24:71-80, 1998.

*** Ellison N. and Jones D.R. Hemostasis during cardiopulmonary Bypass, In Tinker J.H. "1989":**

Cardiopulmonary Bpass, current concepts and controversies, Philadelphia, PA, saunders, 99-108

*** Essell JH, Marin TJ, Salinas J, et al:**

Comparison of TEG to BT and standard coagulation tests in patients after CPB. J cardiothorac. Vasc. Anesth 7:410- 415,1993.

*** Evans DA, Holdet RL, Braun WJ, et al.:**

Post operative blood loss following CPB.

Eur J cardiothorac surg 8 (1): P 25-9, 1994.

*** Feinstein DL. Diagnosis and management of disseminated intravascular coagulation:**

The role of heparin therapy, Blood; 60:284-7, 1982,

*** Fourrier F, Chopin C, Goudemand J et al.:**

Septic shock, multiple organ failure, and disseminated intravascular coagulation. Chest 101:816, 1992.

*** Friesen RH; campbell DN; Clarke DR; Tornabene MA:**

Modified ultrafiltration attenuates dilusional coagulopathy in pediatric open heart operations. Ann throac. Surg. Dec: 64(6):p1787-9, 1997.

*** Fuhrman B. P, Hernan L. J, Rotta A. T, et al.:**

Pathophysiology of cardiac ECC. Artif Organs (US), 23(11) p966-9, Nov1999.

References

*** Garcia-Renaldi R, Simmons P, Salcedoov:**

A technique for spot application of fibrin glue during open heart operations. Ann thoracic Surg. 47-59, 1989.

*** George JN, Woolf SH, Raskob E: HIT:**

A practice guideline developed by explicit methods for American society of haematology. Blood; 88:3-50, 1997.

*** Gillis S, Merin G, Zahger D; et al.:**

Danaproid for CPB in patient with previous heparin induced thrombocytopenia. Br. J. haematol; 98:657-9, 1997.

*** Ginsberg MH, Frelinger AL, Lam SCT, et al.:**

Analysis of platelet aggregation disorders based on flow cytometric analysis of membrane glycoprotein IIb, IIIa with conformation-specific monoclonal antibodies Blood 76:2017-2023, 1990.

*** Goldman S, copeland T, Mortz T et al.:**

Improvement in graft patency without bleeding complications by postoperative initiation of aspirin therapy after CABG. Thromb Haemostas. 62:33a, 1989.

*** Good nough LT, Johnston Mf and Toy P.T.C.Y:**

The variability of transfusion practice in CABG, JAMA, 265, 86, 1991

*** Gravlee GP, Arora S Lavender SW, et al.:**

Predictive value of Blood Clotting tests in cardiac surgical patients. Ann throac surg 58:216-221, 1994.

*** Gravlee GP, Haddon WS, Rothberger K; et al.:**

Heparin dosing and monitoring of CPB.

J thorac cardiovasc. Surg 99:518, 1995.

*** Gravlee GP:**

Dermatan sulphate anticoagulation future replacement of heparin? J cardiothorac vasc Anesth 9:237-239, 1995.

References

*** Harmon DE:**

Cost benefit analysis of pharmacologic hemostasis. Ann thorac surg 61(2suppl): S 21- S 25, 1996.

*** Hartstein G, Jan sens M:**

Of excessive mediastinal bleeding after CPB.

Ann thorac surg; 62 (6): P196-4, Dec 1996.

*** Hathaway WE, Goodnight SH Jr.:**

Disorders of Hemostasis and thrombosis. New York: MCG raw-Hill; 1993.

*** Hett DA, alker D, Pilkington SN, Smith DC:**

Sonoclot analysis. Br. J. Anaesth. 75: 771-776, 1995.

*** Hewitt RL, Chun KL, Flint LM:**

Current clinical concepts in peroperative anticoagulation

Ann. J. Surg.; 3:270-3, 1999.

*** Hird RB:**

Different systemic effects of protamine sulphate on myocyte contractile process circulation 92 (9 suppl):II 433-II 446, 1995.

*** Hiroura M, Furusawa T, Amino M, et al.:**

Clinical experience of a vacuum – assisted nonroller ECC system.

J Extra Corpor. Technol. (US), 32 (3) p148 – 51, Sep. 2000.

*** Horrow JC, DiGregorio GJ, Ruch E:**

The dose-plasma concentration relationship of tranexamic acid during surgery.

Ann J Ther 1:206-209, 1994.

*** Howland WS, Schweizer O, Fleisher M et al.:**

Fibrinogen and albumin deficiencies associated with packed red blood cell transfusion. Anesth Analg 54:89, 1987.

*** Hoyle CF, Swirsky DM, Freedman L, Hayhoe FGJ.:**

Beneficial effects of heparin in management of patient with APL. Br. J. Haematol; 88:283-9, 1998.

References

*** Hull Dr, Pineo GF, Stein P:**

Heparin and low molecular weight heparin for venous thrombo embolism. The twilight of anticoagulant Monitoring. In t. Angiol; 17:213-24, 1998.

*** Jackson SR, Carter JM: platelets:**

Lab measurement and clinical application Blood Rev 7:104-113, 1993.

*** Jan Horrow M.D.:**

Transfusion medicine and coagulation Disorders. In Joel A. Kaplan Anaesth (21):p 1111: 1154, 1999.

*** Joel A. Kaplan, Jan Horrcio M.D.:**

Transfusion medicine and coagulation disorder.

Cardiac anaesthesia 31 : 1111-1154, 1999.

*** Jones A, Geczy CL):**

Thrombin and factor Xa enhance the production of interleukin-1.

Immunology 71:236-241, 1990.

*** Juhan-vague I; Alessi Mc; Declerck PJ.:**

Pathophysiology of fibrinolysis. Baillieres clin haematol 8(2) P 239-43, 1995
Jun.

*** Kaplan K, Francis C:**

Heparin induced thrombocytopenia Blood Rev.; 13:1-7, 1999.

*** Karshi JM, Teasdale SJ; Norman P; caroll J; et al.:**

Prevention of bleeding after CPB with high dose tranexamic acid. J thorac cardiovasc surg 110(3): p 835-42, Sep.1995.

*** Kearon C, Hirsh J:**

Management of anticoagulation before and after elective surgery.

N Engl. J Med; 336:1506-11., 1997.

*** Kearon C, Jack S, Dima SD:**

Heparin resistance & antithrombin III activity.

Int. Angiol; 4:157-10, 1999.

References

*** Kessler CM:**

Pharmacology of aspirin, heparin, coumarin, and thrombolytics agent. Chest 99:975, 1997.

*** Kestin A. S., Valeri C.R, and Khuri S.F.:**

Platelet function Defect of CPB. Blood, 82, 107-117, 1993.

*** Kettner Sc, Kozek SA, Groetzner JP, et al.:**

Effects of hypothermia on TEG in patients undergoing CPB.

Br. J. Anaesth.; 80(3) : P313-7, Mar 1998.

*** Khuri S.F, Wolfe JA, Josa M, et al.:**

Hematologic changes during and after CPB and their relationship to Bleeding time and non surgical Blood loss. J thoroc cardiovasc. Surg. 104:94-107, 1992.

*** Killipt (1988):**

Twenty years of CABG, North England Journal of Med, 319, 366.

*** Kratzer MMA, Born GVR:**

Stimulation of primary hemostasis in vitro hemostasis 15:357-362, 1985.

*** Kumar R; Begain S; Hemker HC:**

Influence of fibrinogen and fibrin on thrombin generation. Thromb Haemast Nov; 72(5):P713-21, 1994.

*** Kutunen A. H, Heikkila LJ, Salmeneera MT.:**

CPB with heparin-coated circuits and reduced systemic anticoagulation.

Ann thorac Surg. 63: 438-444, 1997.

*** Lassen MR, Borris LC, Christiansen HM, et al.:**

Prevention of thromboembolism in 190 hip arthroplasties. Acta orthop scan 62:33,1991.

*** Lauralee Sherwood:**

Blood & Haemostasis, human physiology: 352-372, 1997.

*** Lee CA, Bolton-Maggs P.:**

Guidelines for management of factor XI deficiency. Prepared in Feb. 1998 on UKHCDO.

References

*** Lee CA, Daris MH:**

Guidelines for management of HIT. UKHCDO Feb 1998.

*** Lee WH Jr. Hairston P:**

Structural effects on blood proteins at the gas-blood interface. Fed Proc; 30:1615-1620, 1971.

*** Lemmer JH, Stanford W, Bonney SL, et al.:**

Aprotinin for CABG. Effect on renal function. Ann thorac surg. 59:132, 1995.

*** Leverett LC, Hellums JD, Alfrey CP, Lynch EC:**

Red blood cell damage by shear stress.

Biophys J; 12:257-273, 1992.

*** Levy JH, Faraj BA, Zaidan JR, et al.:**

Effects of different rates of protamine reversal of heparin anticoagulation.

Surgery 119:123-128, 1996.

*** Lind SE:**

Bleeding time does not predict surgical Bleeding, Blood, 77:2547-2552, 1991.

*** Livingston ER: Fisher CA, Tood BA, et al:**

increased activation of coagulation and fibrinolytic systems leads to hemorrhagic complications during left ventricular assist implantation. Circulation 1;94 (9 suppl): PII 227-34, Nov 1996.

*** Loscalzo J, valeri CR, Khuri SF:**

Heparin causes platelet dysfunction and induces fibrinolysis before CPB. Ann thorac sug.: 61(5):1590-1, May 1996

*** Luchman-Jones L; Broze GJ:**

Current status of coagulation. Ann Med.; 27(1): P47-52, Feb 1995.

*** Ludlam CA:**

Clinical heamatology, Churchill Livingstone, Edinburgh. For information regarding investigative procedures, 1990

*** Lyman DJ, Knutson K, McNeil B, Shibatani K:**

The effects of chemical structure and surface properties of synthetic polymers on the coagulation of blood. IV.

The relation between polymer morphology and protein adsorption. Trans Am Soc Artif Intern Organs; 21:49-54, 1995.

*** Mackie I. J. and Neal CR:**

Platelet and vessel wall interaction. Sprenger-veslag, London, 1-32, 1988.

*** Mainerie P, covaia G, et al.:**

Post operative bleeding after CABG comparison between tranexamic acid & E-amino caproic acid. Menerva cardioanyiol: 48(6): P155-160, Jun 2000.

*** Mant MJ, King EG:**

Severe, acute disseminated intravascular coagulation. Am J Med 67:557, 1979.

*** Manucci PM, Anon:**

Transfusion form of treatment for congenital and acquired bleeding disorders, Blood; 72:1449-55, 1998.

*** Mattox KL:**

Blood replacement in major vascular surgery, In Rutherford R.B, Vasc. Surgery Philadelphia, PA, Saunders, 308:1984.

*** Messina A, Davies DJ, Ryan GB:**

Protamine sulphate induced proteinurea: roles of glomerular injury and depletion of polyanion. J pathol 158:147,1989.

*** Messmer KFW:**

Acceptable hematocrit levels in surgical patients. World J Surg 11:41, 1987.

*** Michelsen LG, Kikura M, levy JH, et al.:**

Heparinase I (Neutralase) reversal of systemic anticoagulation. Anesthesiology 85:339-346:1996.

*** Michelson AD, MacGregor H, Bernard MR, et al.:**

Reversible inhibition of human platelet activation by hypothermia in vivo and vitro. Thromb Haemost 71:633-640, 1994.

*** Miller BE; Mochizuki T; levy JH; et al.:**

Predicting and treating coagulopathies after CPB in children: Anesth & analgesia; 85(6): P1196-202, Dec 1997.

*** Miller RD, Robbins TO, Tong MJ et al.:**

Coagulation defects associated with massive blood transfusions. Ann Surg 174:794, 1993.

*** Miller RD:**

Complications of massive blood transfusions. Anesthesiology 39:82, 1993.

*** Miyashita T, NakaJima T, Hayashi Y, et al.:**

Hemostatic effects of low dose protamine following CPB.
Am J Hematol; 64(2) : P112-5, Jun 2000.

*** Mohr R, Golan M, Martinowtzu, et al.:**

Effects of CPB on platelets J thorac cardiovasc durgury 92:434-441, 1986.

*** Morfoll DR, Murphy WG, et al.:**

Synopsis of background papers from the consensus conference on platelet transfusion at the royal college of physicians of Edinburg. 27-28 Nov.
Br J Haematol 1988; 101-609-17, 1997.

*** Mossinger H, Dietrich W:**

Activation of hemostasis during CPB and pediatric aprotinin dosage. Ann throac surg.; 65(6 suppl): ps 45-50; discussion 550-1,574-6, Jun 1998.

*** Murray DJ, Olson J, Strauss R, Tinker JH:**

Coagulation changes during packed red cell replacement of major blood loss. Anesthesiology 69:839, 1992.

*** Muriithi E. W, Belcher P. R, Rao J. N, et al.:**

The effects of heparin & ECC n platelet count and platelet microaggregation during CPB. J Thorac. cardiovasc. surg., 120 (3) page 538 – 34, Sep. 2000.

*** National Institutes of Health Consensus Development Conference Statement:**

Perioperative red cell transfusion. Vol. 7, No. 4, June 27-29, 1988.

References

*** Nevaril CG, Lynch EC, Alfrey Cp, Hellum JD:**

Erythrocyte damage and destruction induced by shearing stress, J Lab Clin Med; 71:784-790, 1988.

*** NIH Consensus Conference:**

Fresh frozen plasma: indications and risks JAMA 253:551, 1985.

*** Nilsson L, Bagge L, Nystroem SO:**

Blood cell trauma and postoperative bleeding: comparison of bubble and membrane oxygenators and observations on coronary suction. Scand J Thorac Cardiovasc Surg; 24:65-69, 1990.

*** Nilsson L, Tyden H, Johansson O, et al:**

Bubble and membrane oxygenators-comparison of postoperative organ dysfunction with special reference to inflammatory activity. Scand J Thorac Cardiovasc Surg; 24:59-64, 1990.

*** Norfolk DR, Williams LM:**

Leucodepletion of Blood products by filtration BJ; 9:19-14, 1995.

*** Novotny WF, Girard TJ, Miletich JP, Broze GJ):**

Platelets secrete a coagulation inhibitor functionally and antigenically similar to the lipoprotein-associated coagulation inhibitor.

Blood 72:2020-2025, 1988.

*** Novotny WF, Girari TJ, Broze GJ):**

Purification of lipoprotein associated coagulation from human plasma J. Boil chem 264:1832-1837, 1989.

*** O'Brein JR:**

shear-induced platelet aggregation. Lancet 335:771-773, 1990.

*** Okwusidi JI, Anvari N, Kulczycky M, et al.:**

Fibrin moderates the catalytic action of heparin but not that of dermatan sulphate on thrombin inhibition in human plasma. J lab. Clin. Med 117:359-364, 1991.

References

*** Orr M:**

Auto transfusion. The use of washed Red cells as an Adjunct to component therapy, surgery, 84, 728:1998.

*** Overm E, Holen EA, Tangen G, et al.:**

Completely heparinized CPB and reduced systemic heparin: clinical and hemostatic effects. Ann thorac surg. 60:365- 371, 1995.

*** Pokhililko AV;**

Research center for hematology Russian academy of Med.sciences: Intrinsic coagulation pathway.

Thromb Res 1;99 (3):P285-93, Aug 2000.

*** Rakower S.R, Worth M.H, and Berman I:**

Hemostatic changes following Massive transfusion in Dogs, Journal of trauma, 133, 633-646, 1996.

*** Rao LV, Rapaport SI, Lorenzi M):**

Enhancement by human umbilical vein endothelial cells of factor Xa-catalyzed activation of factor VII Blood 71: 791-796, 1988.

*** Rapaport S.I. (1983):**

Preoperative Hemostatic evaluation, which test if only? Blood,61, 229-231.

*** Ray MJ, Hawson GA, Just SJ, et al.:**

Relationship of platelet aggregation to bleeding after C.P.B. Ann thoracic Surg. 57:981-986, 1994.

*** Richard C, Woodman and Laurence A. Harker:**

Bleeding complications associated with CPB. Blood, vol. 76,: pp1680-1697, November (1)1990.

*** Richard LEE, Thomas C, JoHh-W. athens, et al.:**

Diagnostic approach to the bleeding disorders. 1301 : 1324 - 48 Philadelphia 1993.

References

*** Riewald M, Reiss H:**

Cryosupernatant as replacement fluid for plasma exchange in thrombotic thrombocytopenic purura. *Br.J.Haematol*, 94:383-6, 1996.

*** Rinder CS, Matthew JP, Rinder HM, et al.:**

Modulation of platelet surface adhesion receptors during EPB. *Anesthesiology* 75:563-570, 1993.

*** Saito T, Sumithran E, Glasgow EF, et al.:**

The enhancement of aminonucleoside nephrosis by Co-administration of protamine.

Kidney Int 32:691, 1987.

*** Saleem A, Blifield C, Shaleh SA, et al:**

Viscoelastic measurement of clot formation. A new test of platelet function. *Ann clin lab sci* 13:115-124, 1993.

*** Samama MM, Boral, Goutin-Thibaul TJ:**

New data on pharmacology of heparin and LMW heparins.

Drugs 52 (suppl) 7:8-14, 1996.

*** Sawyer PN, Wu KT, Weslowski SA, Brattain WH, Boddy PJ. Bioelectric phenomena and intravascular thrombosis:**

The first 12 years. *Surgery*; 56:1020-1026, 1994.

*** Shore-Lesserson L, Fisherc, Ammar T, et al.:**

Comparison of Hemostasis with flow cytometric analysis of platelet function during cardiac surgical procedures. *Anesth & Analg*. 84:SCA 108, 1997.

*** Shore-Lesserson L, rich DL, Vela-cantos, et al.:**

Tranexamic acid reduces transfusion and mediastinal drainage in repeat cardiac surgery. *Anaesth Analg* 83:18, 1996.

*** Slaughter TF, Lebleu TH, Douglas JM, et al.:**

Characterization of protamine neutralization of heparin after CPB. *Anesthesiology* 90:330, 1996.

References

*** Smith CR:**

Management of Bleeding complications in redo cardiac operation.

Ann thorac surg; 65 (4 suppl): PS 2:8, discussion S27-8, Apr 1998.

*** Smith OP, while B, Vaughan D, Rafferty M, Claffey L, et al:**

Use of protein C concentrate, heparin and haemodiafiltration in meningococcal induced purpura fulminans. Lancet; 360:1590-3, 1997

*** Sox HC:**

Probapility theory in the use of diagnostic tests. Ann intenal Med.; 105-69, 62, 1996.

*** Spiess BD, Gillies BS, chankler W, et al:**

Changes in transfusion medicine and exploration rate after insitution of a blood management program in cardiac surgical patients. J cardiothorac vasc. Anesth. 9:168-173, 1995.

*** Spiess BD:**

TEG and CPB. Semin Thromb He most 21 suppl 4:27-33, 1995.

*** Stechling LC, Ellison N, Faust RJ et al.:**

A survey of transfusion practices among anesthesiologists. Vox Sang 52:60, 1987.

*** Still RA, Mc Do well IWF:**

Inadequate heparin neutralization after CPB. Lancet; 350:1590-3, 1999.

*** Straytz RL, Nelson JM, Meyer EA, Shulman IA:**

Compatibility of ADSOL-stored red sells with intravenous solutions. Am J Emarg Med 7:162 1993.

*** Stuart E. Lind, Robert J. Hamdin:**

Evaluation of patients for potential Bleeding disorders, Hematology; 21.2:21.7-21 1996.

*** Suchman AL, Mushlin AL:**

How well does the activated partial thromboplastin time predict post operative hemorrhage; JAMA, 256:750-753, 1986.

References

*** Suzuki Y, Hillyer P, Miyamoto S, et al.:**

Intigritin prevent prolongation of bleeding time after CPB. *Ann Thorac. Surg.*: 66: 373-81, 1998.

*** Tabuchi N, Tigchelaar I, et al.:**

Monitoring coagulation in aprotinin treated patients during heart operation. *Ann Thorac. Surg.* 58:774-777, 1994.

*** Tabuchi N, Tigchelaar I, Van Oeveren W:**

Shear-induced pathology of platelet function in cardiac surg. *Semin Thromb Hemost.* 21:66-70, 1995.

*** Takada A, Takada Y, Mori T; et al.:**

Prevention of severe bleeding by tranexamic acid. *Thromb Res* 58.101,1990.

*** Teufel Sabauer H, Paroid L S, Havel M, et al.:**

A Early activation of hemostasis during CPB. Evidence for thrombin-mediated hyperfibrinolysis. *Thromb Haemost* 68: 250, 252, 1992.

*** Trholm C, Broeng L, Jorgensen PS, et al.:**

Thromboprophylaxis by LMW heparins.

J Bone Joint Surg 73-B:434, 1991.

*** Tuman KJ, McMarthy RJ, Djuric M, et al:**

Evaluation of coagulation during CPB with a heparinase-modified TEG unsay.

J acdiothorac. Vasc. Anesth. 8:144-149, 1994.

UK transfusion services:

Information sheet on fresh frozen plasma, 25 July 1997.

*** United Kingdom Haemophilia center Directors Organization:**

Executive committee. Guidelines on therapeutic products to treatment haemophilia and other hereditary coagulation disorders. *Haemophilia*; 3:63-77, 1997.

*** Urano H, Karasaki Y, Shirahata A:**

Progress in research of Blood coagulation system. *Cardiol*; 82 suppl. 5:13-21 1999.

References

*** V.J. Martlew:**

Perioperative management of patient with coagulation disorders, British Journal of anesthesia 85 (3): 446-55 2000.

*** Valeri CR, Khabbaz K, Khuri SF, et al:**

Effects of skin temperature on platelet function in patients undergoing CPB. J thorae cordiovasc. Surg. 104:108,1992.

*** Van Riper DF, Heres E, Bennett JA, et al.:**

Neutralase 7 mcg/kg reverses heparin-induced prolongation of ACT Better than 5 mcg/kg in patient undergoing CABG.

Anesth. 87:A95, 1997.

*** Vang SN, Stammers AH, Mejak BL, et al.:**

Co-administration of aprotinin & epsilon-amino caproic acid during CPB. J extra-corp techol; 32(4): 196-206, Dec. 2000.

*** Von Willebrand Working party:**

Guidelines for diagnosis and management of Von Willebrand disease Prepared in 1995 on behalf of UK Haemophilia center Directors organization.

*** Wahba A, Rothe G, Lodes H, et al.:**

Effect of ECC and heparin on platelet surface antigens following heart surgery. Thromb. Res. (US), 97 (6) p 379 – 86, 15 Mars. 2000.

*** Wakefield TW, Andrews PC, Wroblewski SK, et al.:**

Effective and less toxic reversal of LMW heparin by a designer variant of protamine. J Vasc Surg 21:839-850, 1995.

*** Weitz JJ:**

LMW heparins.

N Engl J Med 337:688-698, 1997.

*** Williams, W.J., et al.:**

Hematology. 4th ed. New York, MC Graw-Hill book Co. 1990.